SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing significant selling pressure amid retail investor frustration over executive compensation packages and a perceived lack of new high-profile customer contracts. While some community members remain focused on long-term infrastructure potential and oversold technical conditions, others are pivoting toward competitors, viewing recent corporate spending and dilution as clear bearish signals.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility as investors engage in broad sector profit-taking and de-risking across AI-linked semiconductor and memory stocks. The community remains deeply divided, with bulls pointing to long-term demand and aggressive price targets from analysts, while bears argue the sector is undergoing a necessary correction after an unsustainable parabolic rally.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is trending as traders analyze a multi-year supply agreement with Coherent, which provides significant capital prepayment and validates long-term demand for the company's indium phosphide substrates. While some community members highlight this as a key indicator of semiconductor supply chain strength and forward visibility, others are actively debating whether recent volatility and insider selling patterns signal an overextended valuation.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is rallying on strong production and delivery figures that exceeded guidance, sparking community optimism about the R2 platform's potential as a primary growth catalyst. While some investors remain cautious about long-term profitability and execution risks, many are actively discussing the stock's role as a major competitor to Tesla, viewing the recent momentum as a potential turning point for its long-term valuation.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp is trending as investors digest the company's recent earnings report and analyze the ongoing demand for optical networking components within the AI infrastructure ecosystem. The community remains highly focused on the company's vertically integrated InP production capabilities and its multi-year supply agreements, which many see as a crucial hedge against supply chain bottlenecks in the race to scale data center connectivity.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Investors are closely tracking the 80th event milestone in the REGAL Phase 3 trial for galinpepimut-S, with community sentiment fueled by expectations of a major data readout or potential buyout announcement ahead of the long holiday weekend. The stock is seeing significant volume and price volatility as traders debate the implications of trial delays and the potential for a substantial revaluation if clinical endpoints are met.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is currently attracting intense investor interest as market participants digest analyst price target upgrades and a $500 million expansion of its Singapore manufacturing facility to support global AI chip demand. The community remains heavily focused on the stock's role as a critical infrastructure provider, with traders actively debating its valuation against equipment sector peers amidst broader semiconductor cycle volatility.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is gaining significant community attention as shareholders focus on upcoming data readouts for its dermatological pipeline, while speculation persists regarding potential M&A activity and legal developments involving Eli Lilly. Investors remain intensely focused on the drug candidate's durability and long-term efficacy, which many view as a potential differentiator in the competitive autoimmune market.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending following reports that the company plans to monetize excess AI compute capacity by offering cloud-style services, a move that has sparked intense debate over the company's long-term infrastructure strategy and the health of the broader AI ecosystem. Community discussion remains polarized, with some investors viewing the pivot as a smart way to maximize returns on massive capital spending, while others fear it signals cooling demand for the company's internal AI agents and suggests a more crowded, competitive landscape for AI infrastructure.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is surging as retail sentiment leans into a high-risk humanoid robotics narrative driven by Agility Robotics' commercial momentum and recent institutional backing from BlueCrest Capital. Investors are closely tracking the SPAC merger process, balancing the excitement of potential category leadership against common volatility risks associated with pre-revenue SPAC transactions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment

Equity

The biotech moves a step closer to full approval in IgAN as regulators agree to an accelerated timeline for key kidney function data review.

Pictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERA

Pictet Asset Management Holding SA cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 3.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,392,421 shares of the company's stock after sellin...

Vera Therapeutics (VERA) to Release Earnings on Tuesday

Vera Therapeutics (NASDAQ:VERA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...

Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 22,951 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 22,951 shares of the company's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the transaction, the...

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and t...

Vera Therapeutics (NASDAQ:VERA) CEO Sells $1,010,991.55 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 22,951 shares of the company's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive...

AMI Asset Management Corp Makes New $1.44 Million Investment in Vera Therapeutics, Inc. $VERA

AMI Asset Management Corp bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

Vera Therapeutics (NASDAQ:VERA) Stock Price Up 7.1% - What's Next?

Vera Therapeutics (NASDAQ:VERA) Trading Up 7.1% - Here's What Happened...

JPMorgan Chase & Co. Sells 228,182 Shares of Vera Therapeutics, Inc. $VERA

JPMorgan Chase & Co. cut its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 73.5% in the third quarter, according to the company in its most recent disclosure with the...

E. Ohman J or Asset Management AB Invests $2 Million in Vera Therapeutics, Inc. $VERA

E. Ohman J or Asset Management AB purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the fourth quarter, according to the company in its most recent 13F...

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Traders are closely tracking the upcoming July 7th FDA approval decision, with sentiment leaning toward a high probability of success.

The stock experienced volatility following competitor clinical trial results, sparking debate over comparative drug efficacy and market positioning.

Investors are weighing whether recent price dips and stop-loss triggers represent a malicious short-interest raid or a buying opportunity.

With analysts maintaining optimistic price targets as high as $78, long-term holders are debating the valuation upside versus recent downward pressure.

Feed

News

Sentiment

Earnings

Fundamentals

Info

VERAVera Therapeutics Inc - Ordinary Shares - Class A

Fundamentals

Latest VERA News